tiprankstipranks
Blurbs

Enanta Pharmaceuticals (ENTA) Receives a Sell from Evercore ISI

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Sell rating on Enanta Pharmaceuticals (ENTAResearch Report), with a price target of $35.00. The company’s shares closed last Friday at $70.44.

According to TipRanks.com, Bayko is a 4-star analyst with an average return of 8.6% and a 44.0% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Kiniksa Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for Enanta Pharmaceuticals with a $85.00 average price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $102.00 and a one-year low of $40.37. Currently, Enanta Pharmaceuticals has an average volume of 213.2K.

Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ENTA in relation to earlier this year. Last month, Jay Luly, the President & CEO of ENTA bought 10,063 shares for a total of $118,442.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Read More on ENTA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More